Medical - Diagnostics & Research
Compare Stocks
4 / 10Stock Comparison
DGX vs UNH vs CVS vs VEEV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Information Services
DGX vs UNH vs CVS vs VEEV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Information Services |
| Market Cap | $21.12B | $335.60B | $111.40B | $27.35B |
| Revenue (TTM) | $11.28B | $449.71B | $407.90B | $3.20B |
| Net Income (TTM) | $1.02B | $12.04B | $2.93B | $909M |
| Gross Margin | 33.2% | 18.8% | 13.9% | 75.5% |
| Operating Margin | 14.3% | 4.2% | 1.5% | 28.7% |
| Forward P/E | 17.8x | 20.2x | 12.2x | 19.0x |
| Total Debt | $6.92B | $78.39B | $93.59B | $96M |
| Cash & Equiv. | $420M | $24.36B | $8.51B | $1.42B |
DGX vs UNH vs CVS vs VEEV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Quest Diagnostics I… (DGX) | 100 | 161.3 | +61.3% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
| Veeva Systems Inc. (VEEV) | 100 | 76.9 | -23.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DGX vs UNH vs CVS vs VEEV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DGX is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 181.3% 10Y total return vs VEEV's 5.2%
- Lower volatility, beta 0.07, Low D/E 95.0%, current ratio 1.04x
UNH is the clearest fit if your priority is dividends.
- 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 19.0x)
- Beta 0.05 vs VEEV's 0.77
VEEV is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
- 16.3% revenue growth vs CVS's 7.8%
- 28.4% margin vs CVS's 0.7%
- 11.1% ROA vs CVS's 1.1%, ROIC 12.9% vs 5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (12.2x vs 19.0x) | |
| Quality / Margins | 28.4% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs VEEV's 0.77 | |
| Dividends | 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +34.7% vs VEEV's -29.4% | |
| Efficiency (ROA) | 11.1% ROA vs CVS's 1.1%, ROIC 12.9% vs 5.0% |
DGX vs UNH vs CVS vs VEEV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DGX vs UNH vs CVS vs VEEV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VEEV leads in 2 of 6 categories
CVS leads 2 • DGX leads 1 • UNH leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VEEV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 140.7x VEEV's $3.2B. VEEV is the more profitable business, keeping 28.4% of every revenue dollar as net income compared to CVS's 0.7%. On growth, VEEV holds the edge at +16.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $11.3B | $449.7B | $407.9B | $3.2B |
| EBITDAEarnings before interest/tax | $1.9B | $23.2B | $10.5B | $956M |
| Net IncomeAfter-tax profit | $1.0B | $12.0B | $2.9B | $909M |
| Free Cash FlowCash after capex | $1.3B | $19.7B | $7.4B | $1.4B |
| Gross MarginGross profit ÷ Revenue | +33.2% | +18.8% | +13.9% | +75.5% |
| Operating MarginEBIT ÷ Revenue | +14.3% | +4.2% | +1.5% | +28.7% |
| Net MarginNet income ÷ Revenue | +9.1% | +2.7% | +0.7% | +28.4% |
| FCF MarginFCF ÷ Revenue | +11.8% | +4.4% | +1.8% | +43.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.2% | +2.0% | +6.2% | +16.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.5% | +0.7% | +63.1% | +23.9% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 21.8x trailing earnings, DGX trades at a 65% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, DGX's 12.7x EV/EBITDA is more attractive than VEEV's 28.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $21.1B | $335.6B | $111.4B | $27.4B |
| Enterprise ValueMkt cap + debt − cash | $27.6B | $389.6B | $196.5B | $26.0B |
| Trailing P/EPrice ÷ TTM EPS | 21.81x | 27.95x | 62.81x | 30.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.77x | 20.19x | 12.19x | 18.98x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.70x |
| EV / EBITDAEnterprise value multiple | 12.71x | 16.70x | 13.11x | 28.40x |
| Price / SalesMarket cap ÷ Revenue | 1.91x | 0.75x | 0.28x | 8.56x |
| Price / BookPrice ÷ Book value/share | 2.96x | 3.31x | 1.47x | 3.89x |
| Price / FCFMarket cap ÷ FCF | 15.54x | 20.88x | 14.27x | 19.33x |
Profitability & Efficiency
VEEV leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DGX delivers a 13.8% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $4 for CVS. VEEV carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), DGX scores 7/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.8% | +11.5% | +3.9% | +13.4% |
| ROA (TTM)Return on assets | +6.3% | +3.9% | +1.1% | +11.1% |
| ROICReturn on invested capital | +8.8% | +9.2% | +5.0% | +12.9% |
| ROCEReturn on capital employed | +11.5% | +9.7% | +6.1% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.95x | 0.77x | 1.24x | 0.01x |
| Net DebtTotal debt minus cash | $6.5B | $54.0B | $85.1B | -$1.3B |
| Cash & Equiv.Liquid assets | $420M | $24.4B | $8.5B | $1.4B |
| Total DebtShort + long-term debt | $6.9B | $78.4B | $93.6B | $96M |
| Interest CoverageEBIT ÷ Interest expense | 6.26x | 4.71x | 2.11x | — |
Total Returns (Dividends Reinvested)
DGX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DGX five years ago would be worth $14,771 today (with dividends reinvested), compared to $6,471 for VEEV. Over the past 12 months, CVS leads with a +34.7% total return vs VEEV's -29.4%. The 3-year compound annual growth rate (CAGR) favors DGX at 14.1% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +10.8% | +10.6% | +10.6% | -23.4% |
| 1-Year ReturnPast 12 months | +9.9% | -3.2% | +34.7% | -29.4% |
| 3-Year ReturnCumulative with dividends | +48.5% | -19.9% | +36.6% | -5.2% |
| 5-Year ReturnCumulative with dividends | +47.7% | -2.6% | +17.0% | -35.3% |
| 10-Year ReturnCumulative with dividends | +181.3% | +220.6% | +3.5% | +519.4% |
| CAGR (3Y)Annualised 3-year return | +14.1% | -7.1% | +11.0% | -1.8% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than VEEV's 0.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs VEEV's 54.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.07x | 0.59x | 0.05x | 0.77x |
| 52-Week HighHighest price in past year | $213.50 | $395.52 | $88.63 | $310.50 |
| 52-Week LowLowest price in past year | $164.65 | $234.60 | $58.35 | $148.05 |
| % of 52W HighCurrent price vs 52-week peak | +89.4% | +93.5% | +98.5% | +54.2% |
| RSI (14)Momentum oscillator 0–100 | 40.1 | 75.9 | 69.3 | 49.6 |
| Avg Volume (50D)Average daily shares traded | 841K | 7.9M | 7.4M | 2.3M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DGX as "Hold", UNH as "Buy", CVS as "Buy", VEEV as "Buy". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs DGX's 1.64%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $220.57 | $385.43 | $95.20 | $280.10 |
| # AnalystsCovering analysts | 34 | 52 | 41 | 42 |
| Dividend YieldAnnual dividend ÷ price | +1.6% | +2.4% | +3.1% | — |
| Dividend StreakConsecutive years of raises | 15 | 25 | 0 | — |
| Dividend / ShareAnnual DPS | $3.12 | $8.70 | $2.67 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.1% | +1.7% | 0.0% | +0.6% |
VEEV leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
DGX vs UNH vs CVS vs VEEV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DGX or UNH or CVS or VEEV a better buy right now?
For growth investors, Veeva Systems Inc.
(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DGX or UNH or CVS or VEEV?
On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 21.
8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — DGX or UNH or CVS or VEEV?
Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.
7%, compared to -35. 3% for Veeva Systems Inc. (VEEV). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DGX or UNH or CVS or VEEV?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Veeva Systems Inc. 's 0. 77β — meaning VEEV is approximately 1430% more volatile than CVS relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — DGX or UNH or CVS or VEEV?
By revenue growth (latest reported year), Veeva Systems Inc.
(VEEV) is pulling ahead at 16. 3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, VEEV leads at 14. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DGX or UNH or CVS or VEEV?
Veeva Systems Inc.
(VEEV) is the more profitable company, earning 28. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus 2. 6% for CVS. At the gross margin level — before operating expenses — VEEV leads at 75. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DGX or UNH or CVS or VEEV more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.
08Which pays a better dividend — DGX or UNH or CVS or VEEV?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), DGX (1. 6% yield) pay a dividend. VEEV does not pay a meaningful dividend and should not be held primarily for income.
09Is DGX or UNH or CVS or VEEV better for a retirement portfolio?
For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
07), 1. 6% yield, +181. 3% 10Y return). Both have compounded well over 10 years (DGX: +181. 3%, VEEV: +519. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DGX and UNH and CVS and VEEV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DGX is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; VEEV is a mid-cap high-growth stock. DGX, UNH, CVS pay a dividend while VEEV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.